tiprankstipranks
Protagonist Therapeutics participates in a conference call with Truist
PremiumThe FlyProtagonist Therapeutics participates in a conference call with Truist
14d ago
Protagonist Therapeutics: Promising Pipeline and Strategic Partnerships Drive Buy Rating
Premium
Ratings
Protagonist Therapeutics: Promising Pipeline and Strategic Partnerships Drive Buy Rating
14d ago
Promising Potential of Rusfertide in Treating Polycythemia Vera Drives Buy Rating for Protagonist Therapeutics
Premium
Ratings
Promising Potential of Rusfertide in Treating Polycythemia Vera Drives Buy Rating for Protagonist Therapeutics
14d ago
Protagonist Therapeutics price target raised to $58 from $43 at JMP Securities
PremiumThe FlyProtagonist Therapeutics price target raised to $58 from $43 at JMP Securities
3M ago
Protagonist Therapeutics price target raised to $67 from $51 at BTIG
Premium
The Fly
Protagonist Therapeutics price target raised to $67 from $51 at BTIG
3M ago
Protagonist Therapeutics selects PN-881 as development candidate
Premium
The Fly
Protagonist Therapeutics selects PN-881 as development candidate
3M ago
PTGX Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsPTGX Upcoming Earnings Report: What to Expect?
4M ago
Protagonist Therapeutics participates in a conference call with JPMorgan
Premium
The Fly
Protagonist Therapeutics participates in a conference call with JPMorgan
5M ago
Walmart upgraded, Starbucks downgraded: Wall Street’s top analyst calls
Premium
The Fly
Walmart upgraded, Starbucks downgraded: Wall Street’s top analyst calls
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100